Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease

Jianyi Yin; Yassin El-Najjar; Noelle Cordova; Mary-Joe Touma; Noelle Nguyen; Moheb Boktor; Ezra Burstein; David I Fudman

doi:10.1093/ibd/izae105

Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease

Inflamm Bowel Dis. 2024 May 20:izae105. doi: 10.1093/ibd/izae105. Online ahead of print.

Authors

Jianyi Yin¹, Yassin El-Najjar¹, Noelle Cordova¹, Mary-Joe Touma¹, Noelle Nguyen², Moheb Boktor¹, Ezra Burstein¹, David I Fudman¹

Affiliations

¹ Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
² University of Houston College of Pharmacy, Houston, TX, USA.

PMID: 38767984
DOI: 10.1093/ibd/izae105

No abstract available

Keywords: JAK inhibitor; biologic therapy; inflammatory bowel disease; upadacitinib.

Plain language summary

We report that upadacitinib intended for short-term use in combination with biologic therapy appeared to be effective in inducing steroid-free clinical remission in patients with active inflammatory bowel disease, but a substantial proportion of patients required extended use.